Mapping the Non-Drug Toolkit That Helps Head and Neck Cancer Patients Survive Chemoradiotherapy

Head and neck cancer is one of the most demanding diagnoses in oncology, not only because of the disease itself but because of the treatment designed to cure it. When patients undergo chemoradiotherapy, the intense combination of radiation and chemotherapy that targets tumors of the mouth, throat, larynx, and nasal passages, the collateral damage can be severe. Painful swallowing, dry mouth, thickened saliva, loss of taste, skin breakdown, fatigue, trismus, and psychological distress frequently accumulate as therapy progresses, eroding quality of life and sometimes forcing patients to interrupt or abandon treatment altogether. A new scoping review published in BMC Complementary Medicine and Therapies has now mapped, for the first time in a systematically comprehensive way, the landscape of non-pharmacological interventions developed to help these patients through the peri-chemoradiotherapy period, and the picture it paints is both encouraging and sobering.

The review, led by Jianxia Lyu and Fang Li as co-first authors, with Shichuan Zhang and Aiping Wang as corresponding authors, was conducted by a team based at Sichuan Cancer Hospital and the Affiliated Cancer Hospital of the University of Electronic Science and Technology of China, along with collaborators at China Medical University in Shenyang. The researchers set out to answer a deceptively simple question: what non-drug approaches exist to manage symptoms in head and neck cancer patients during and around chemoradiotherapy, and how well have they been developed and tested? Although clinical guidelines already recommend non-pharmacological strategies for symptom management, no comprehensive overview of the field existed, leaving clinicians, researchers, and patients without a clear map of what has been tried, what has worked, and where the gaps lie.

To build that map, the team followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews, known as PRISMA-ScR, a rigorous checklist that governs how scoping reviews are conducted and reported. They searched PubMed, Scopus, Embase, and other databases from their inception through May 2025, capturing decades of published research. The search yielded 68 eligible studies, each of which the reviewers analyzed through the lens of the United Kingdom Medical Research Council’s complex intervention framework, a widely respected methodological scaffold that treats health interventions not as single pills but as layered programs with distinct phases of development, feasibility testing, evaluation, and implementation. This framework allowed the authors to ask not just whether interventions exist, but how they were designed, who delivered them, where they took place, what outcomes they measured, and what obstacles stood in their way.

The findings reveal a field that is active but fragmented. The 68 studies described interventions falling into nine distinct categories, spanning approaches such as exercise programs, swallowing and jaw rehabilitation, oral care regimens, psychological and cognitive behavioral support, educational programs, traditional Chinese medicine practices, and technology-assisted interventions including exergames such as the PafitME physical activity program with fitness-graded motion games and the ENHANCE exercise program adapted for neurologic and head and neck cancer patients. Nurses emerged as the primary deliverers of these interventions, a finding that underscores the central role of oncology nursing in supportive cancer care. Perhaps most strikingly, the majority of interventions were conducted in home settings rather than clinics or hospitals, reflecting a growing recognition that symptom management must reach patients where they actually live, especially during the weeks of daily radiotherapy when travel and fatigue make frequent clinic visits burdensome.

Equally informative is the review’s analysis of how effectiveness was measured. The researchers classified the main outcome measures into six categories, ranging from symptom-specific instruments such as the Xerostomia Questionnaire and the Gothenburg Trismus Questionnaire to broader quality-of-life tools like the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, or EORTC QLQ-C30, and the Xerostomia-related Quality of Life Scale. Functional measures also appeared, including the Penetration-Aspiration Scale and the Functional Oral Intake Scale for swallowing, maximum interincisal opening for jaw mobility, and performance status scales such as the Karnofsky Performance Status and the Eastern Cooperative Oncology Group scale. Psychological outcomes were tracked with instruments like the Herth Hope Index, and the review noted measures of symptom distress, benefit-finding, and learned and social resourcefulness, highlighting how modern supportive care research increasingly treats patients as active copers rather than passive recipients of care.

The methodological audit, however, exposes significant weaknesses. By applying the MRC complex intervention framework, the reviewers found that many interventions had not been developed through systematic, theory-driven processes. Intervention development often proceeded without explicit use of behavioral theory or patient input, and pilot testing, the crucial phase in which feasibility, acceptability, and recruitment parameters are established before a full trial, was inconsistently reported. Efficacy evaluations varied widely in design and rigor. Because a scoping review maps the literature without formally assessing study quality or synthesizing effect sizes, the review does not declare any single intervention definitively effective. What it does declare, forcefully, is that the field lacks the standardization needed to compare results across studies, replicate successful programs, or build the cumulative evidence base that guideline committees require.

The implementation analysis may prove to be the review’s most practically valuable contribution. The authors categorized facilitators and barriers at four levels: patient, healthcare provider, program design, and system. At the patient level, motivation, symptom burden, and health literacy shaped whether people could engage with demanding home exercise or oral care routines. At the provider level, nursing workload, training, and interdisciplinary coordination determined whether interventions could be delivered consistently. Program design factors included the adaptability of protocols to individual patients and the integration of technology, which could either extend reach or introduce usability problems for older patients. At the systemic level, funding, institutional support, and the absence of standardized care pathways limited scalability and sustainability. This multilevel framing aligns with implementation science thinking and gives future trial designers a concrete checklist of the forces that make or break real-world adoption.

The clinical stakes of this work are considerable. Chemoradiotherapy for head and neck cancer has become more precise with intensity-modulated radiotherapy, or IMRT, which shapes radiation beams to spare healthy tissue, yet acute toxicities remain a defining feature of treatment. Mucositis, dysphagia, and xerostomia can lead to weight loss, feeding tube dependence, and hospitalization, while untreated distress and fatigue undermine adherence to the very therapy that offers cure. If non-pharmacological interventions, delivered largely by nurses in patients’ homes, can reduce even a fraction of this burden, the payoff extends beyond comfort to treatment completion and survival. The review’s emphasis on patient-centered, theory-driven design suggests a path forward: interventions co-created with patients, grounded in behavioral science, tested in rigorous pilots, and embedded in care pathways rather than bolted on as afterthoughts.

The authors conclude with a set of research demands distilled from the included studies, calling for standardized, theory-driven, patient-centered non-pharmacological interventions integrated into head and neck cancer care pathways. They recommend that future trials boost intervention adaptability, strengthen methodological standards, and improve the scalability and sustainability of symptom management programs. The work was supported by the Sichuan Science and Technology Program in China, and the review is published open access under a Creative Commons license, making its detailed mapping of nine intervention categories and six outcome measure categories freely available to clinicians and researchers worldwide. For the growing global population of head and neck cancer survivors, the message is clear: the drug-free toolkit exists, is being delivered largely by nurses at home, and now has a roadmap showing exactly what must improve before it can fulfill its promise.

Subject of Research: Non-pharmacological symptom management for head and neck cancer patients during peri-chemoradiotherapy

Article Title: A scoping review of non-pharmacological symptom management in head and neck cancer patients during the peri-chemoradiotherapy period

Article References: Lyu, J., Li, F., Yin, L., Yang, Q., Zhang, H., Jiang, Q., Cheng, P., Zhang, S., & Wang, A. (2026). A scoping review of non-pharmacological symptom management in head and neck cancer patients during the peri-chemoradiotherapy period. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05573-2

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05573-2

Keywords: head and neck cancer, chemoradiotherapy, non-pharmacological interventions, symptom management, scoping review, nursing, quality of life, xerostomia, dysphagia, MRC complex intervention framework, supportive cancer care, implementation science